233 results
Page 5 of 12
6-K
EX-99.3
329 oqg4i9oky1
30 Sep 22
SciSparc Enters Agreement to Acquire Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
7:27am
6-K
EX-99.1
81gpd4
25 Aug 22
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment
6:54am
6-K
EX-99.1
noh809i2
16 Aug 22
SciSparc Signs a Non-Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal
6:30am
6-K
EX-99.1
5qto6mbo9 qtran
12 Aug 22
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
4:05pm
6-K
EX-99.1
25lh5k3neq
11 Aug 22
Current Report
4:05pm
6-K
EX-99.1
x9hkpsnz828
11 Aug 22
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:42am
6-K
EX-99.1
zni8 6hma4ge
2 Aug 22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
4:00pm
F-3
kkc523i
7 Jul 22
Shelf registration (foreign)
4:22pm
6-K
EX-99.1
aecarrzhrqy2 rz
7 Jul 22
Report of Foreign Private Issuer
4:00pm
6-K
EX-99.1
wgprtljwfx2w5 hjgk
7 Jul 22
Report of Foreign Private Issuer
7:49am
6-K
EX-99.1
och x17ahw1dnp
29 Jun 22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
8:36am
6-K
EX-99.1
l4ymrpfoz yf4
24 Jun 22
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
8:52am
6-K
EX-99.1
zfqzowtn4kr5 gqwppis
9 Jun 22
SciSparc’s Board of Directors Provides Strategic Decision
8:38am
6-K
EX-99.1
4c3p3
2 Jun 22
Report of Foreign Private Issuer
4:30pm
6-K
EX-99.1
dixwq
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.2
57yw46k68
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.1
hfcp69u5f2o8mz
27 May 22
SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market
4:10pm
6-K
EX-99.1
alma 32c63lrnsjqnxx
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am
6-K
EX-99.1
078z85w7z7zaajgw8d3b
24 May 22
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
8:31am
6-K
EX-99.1
cqpgm d905
11 May 22
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors
1:58pm